SPARC concludes enrolment in global Phase 2 study of Vodobatinib in early Parkinson's disease

PROSEEK is global, randomized, double-blind, placebo-controlled Phase 2 study in patients with early Parkinson's disease evaluating the safety and efficacy of Abl tyrosine kinase inhibition using K0706/SCC-138.

The primary endpoint is the change from baseline to week 40 in the score of the MDS-UPDRS Part III (Movement Disorder Society – Unified Parkinson’s Disease Rating Scale).

The key secondary endpoints include:

• Change from baseline to Week 40 in the sum of the MDS-UPDRS Parts II and III total scores

• Time from baseline to initiation of symptomatic medication

• Change in health-related quality of life as measured by the European quality of life questionnaire

• Change in Clinician global impression of severity

Vodobatinib is a potential first-in-class, highly selective and brain penetrating c-Abl inhibitor. Vodobatinib is being evaluated under multiple clinical trials in patients with Parkinson’s disease, Dementia with Lewy Body and Chronic Myelogenous Leukemia.

Read also: Sun Pharma, SPARC collaborate for commercialization of phenobarbital for injection in US